• About Genmab
    • About Genmab
    • Board of Directors
    • Senior Leadership Team
    • Corporate Social Responsibility
    • Partnerships
    • FAQ
  • Science & Research
    • Products In Development
    • Licensing Opportunities
    • Clinical Trials
    • Introduction to Antibodies
    • Antibody Discovery
    • Next Generation Technology
    • Scientific Articles
  • Investor Center
    • InvestorPortal
    • Stock Quotes
    • Financial Calendar
    • Stock Information
    • Analysts
    • Events
    • Investor Contact
    • Corporate Documents
    • Warrant Scheme
  • Press Center
    • Recent News Releases
    • Archived News Releases
    • Press Contact
  • Careers
    • Career Opportunities
  • Contact Genmab
    • Contact Genmab
    • Subscribe to Genmab News

Hot News

Genmab Reaches Second Milestone in Lundbeck Collaboration...»
Arzerra Fourth Quarter and Full Year 2011 Net Sales Figures...»
Genmab Announces Progress with DuoBody™ Platform...»
Genmab Announces Progress with Lundbeck Collaboration ...»
More Genmab News Releases

Investor Center

  • InvestorPortal
  • Stock Quotes
  • Financial Calendar
  • Stock Information
  • Analysts
  • Events
  • Investor Contact
  • Corporate Documents
  • Warrant Scheme
  • Home
Print

Legal Notice
Use of this Site is subject to Important Legal Terms, which you are requested to read prior to proceeding.
© 2011 Genmab A/S
Investor Center » Events » 2011 » Poster: Genmab Announces Preliminary Safety and Efficacy Data for Daratumumab

Poster: Genmab Announces Preliminary Safety and Efficacy Data for Daratumumab

Click the following link to read the poster presented at ASH:

A Phase I/II, Dose-Escalation Study of Daratumumab, a CD38 mAb in Patients with Multiple Myeloma – Preliminary Safety Data
(back to Recent News)